{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:58:40Z","timestamp":1770973120049,"version":"3.50.1"},"reference-count":29,"publisher":"Japan Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0548","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T22:11:43Z","timestamp":1737497503000},"page":"421-435","source":"Crossref","is-referenced-by-count":3,"title":["Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6982-9167","authenticated-orcid":false,"given":"Yuki","family":"Taki","sequence":"first","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan"},{"name":"Research Institute of Disaster Medicine, Chiba University, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuma","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan"},{"name":"Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryunosuke","family":"Kozu","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikki","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan"},{"name":"Research Institute of Disaster Medicine, Chiba University, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Horiguchi","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9761-1750","authenticated-orcid":false,"given":"Tomoaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan"},{"name":"Research Institute of Disaster Medicine, Chiba University, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10: 804\u2013826.","DOI":"10.1016\/S2213-8587(22)00244-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Coopmans EC, van der Lely AJ, Neggers S (2022) Approach to the patient with treatment-resistant acromegaly. J Clin Endocrinol Metab 107: 1759\u20131766.","DOI":"10.1210\/clinem\/dgac037"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Duan L, Zhu H, Xing B, Gu F (2017) Prolonged preoperative treatment of acromegaly with somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1\u20133): a retrospective cohort study conducted at a single center. BMC Endocr Disord 17: 55.","DOI":"10.1186\/s12902-017-0205-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yang C, Li G, Jiang S, Bao X, Wang R (2019) Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and meta-analysis of comparative studies. Sci Rep 9: 14070.","DOI":"10.1038\/s41598-019-50639-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146: 707\u2013716.","DOI":"10.1530\/eje.0.1460707"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, et al. (2018) Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6: 17\u201326.","DOI":"10.1016\/S2213-8587(17)30326-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, et al. (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary 24: 887\u2013903.","DOI":"10.1007\/s11102-021-01161-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Colao A, Bronstein MD, Freda P, Gu F, Shen CC, et al. (2014) Pasireotide <i>versus<\/i> octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99: 791\u2013799.","DOI":"10.1210\/jc.2013-2480"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, et al. (2014) Pasireotide <i>versus<\/i> continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2: 875\u2013884.","DOI":"10.1016\/S2213-8587(14)70169-X"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Tahara S, Murakami M, Kaneko T, Shimatsu A (2017) Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr J 64: 735\u2013747.","DOI":"10.1507\/endocrj.EJ16-0624"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, et al. (2009) Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 71: 237\u2013245.","DOI":"10.1111\/j.1365-2265.2008.03503.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Yamato A, Nagano H, Gao Y, Matsuda T, Hashimoto N, et al. (2022) Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas\/somatotroph pituitary neuroendocrine tumors. Commun Biol 5: 1304.","DOI":"10.1038\/s42003-022-04272-1"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13 Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, et al. (1999) Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48: 77\u201385.","DOI":"10.2337\/diabetes.48.1.77"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, et al. (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98: 3446\u20133453.","DOI":"10.1210\/jc.2013-1771"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, et al. (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary 18: 385\u2013394.","DOI":"10.1007\/s11102-014-0585-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Muhammad A, Coopmans EC, Delhanty PJD, Dallenga AHG, Haitsma IK, et al. (2018) Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol 179: 269\u2013277.","DOI":"10.1530\/EJE-18-0353"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17 Shimon I, Adnan Z, Gorshtein A, Baraf L, Saba Khazen N, et al. (2018) Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62: 448\u2013455.","DOI":"10.1007\/s12020-018-1690-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Gadelha M, Bex M, Colao A, Pedroza Garc\u00eda EM, Poiana C, et al. (2019) Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front Endocrinol (Lausanne) 10: 931.","DOI":"10.3389\/fendo.2019.00931"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, et al. (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 182: 583.","DOI":"10.1530\/EJE-19-0762"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Lu\u017aniak A, Jawiarczyk-Przyby\u0142owska A, et al. (2021) The effect of 6 months\u2019 treatment with pasireotide LAR on glucose metabolism in patients with resistant acromegaly in real-world clinical settings. Front Endocrinol (Lausanne) 12: 633944.","DOI":"10.3389\/fendo.2021.633944"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, et al. (2021) Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73: 658\u2013666.","DOI":"10.1007\/s12020-021-02711-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Akirov A, Gorshtein A, Dotan I, Khazen NS, Pauker Y, et al. (2021) Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine 74: 396\u2013403.","DOI":"10.1007\/s12020-021-02782-2"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23 Stelmachowska-Bana\u015b M, Czajka-Oraniec I, Tomasik A, Zgliczy\u0144ski W (2022) Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary 25: 180\u2013190.","DOI":"10.1007\/s11102-021-01185-w"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Wolf P, Dormoy A, Maione L, Salenave S, Young J, et al. (2022) Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. <i>Endocr Connect<\/i> 11: e220296.","DOI":"10.1530\/EC-22-0296"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, et al. (2023) Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience. J Clin Endocrinol Metab 108: e1571\u2013e1579.","DOI":"10.1210\/clinem\/dgad378"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Corica G, Pirchio R, Milioto A, Nista F, Arecco A, et al. (2024) Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest 47: 683\u2013697.","DOI":"10.1007\/s40618-023-02186-1"},{"key":"27","unstructured":"27 Signifor Recordati rare diseases. Regional Office for Japan, Tokyo, Japan. https:\/\/www.recordatirarediseases.com\/ja\/for-hcp\/signifor accessed on September 19, 2024 (In Japanese)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Breitschaft A, Hu K, Hermosillo Res\u00e9ndiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 103: 458\u2013465.","DOI":"10.1016\/j.diabres.2013.12.011"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 St\u00f6rmann S, Meyh\u00f6fer SM, Groener JB, Faust J, Schilbach K, et al. (2024) Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts\u2019 consensus statement. Front Endocrinol (Lausanne) 15: 1348990.","DOI":"10.3389\/fendo.2024.1348990"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/4\/72_EJ24-0548\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T04:31:35Z","timestamp":1743827495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/4\/72_EJ24-0548\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0548","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0548"}}